Prolonged Anticoagulation After a First Episod of Idiopathic Proximal Deep Vein Thrombosis (PADIS TVP)

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
University Hospital, Brest
ClinicalTrials.gov Identifier:
NCT00740493
First received: August 22, 2008
Last updated: July 7, 2014
Last verified: July 2014
  Purpose

In a French multicenter double blind randomized controlled trial, the main objective is to demonstrate that, after 6 months of oral anticoagulation for a first episode of idiopathic proximal deep vein thrombosis, 18 months of warfarin therapy is associated with a lower cumulative risk of recurrent VTE and major bleeding in comparison with that on 18 months of placebo. The secondary objectives are: (1) to determine the risk of recurrent VTE after 6 months of warfarin therapy and the presence or the absence of residual lung scan perfusion defect and the persistence or not of elevated D-dimer test; and (2), to determine the impact of extended duration of anticoagulation on the risk of VTE after stopping anticoagulant therapy on a follow-up of 2 years.


Condition Intervention Phase
Recurrent Venous Thromboembolism
Idiopathic Deep Vein Thrombosis
Drug: warfarin
Drug: placebo of warfarin
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Eighteen Months of Oral Anticoagulant Therapy Versus Placebo After 6 Six Months of Anticoagulation for a First Episode of Idiopathic Proximal Deep Vein Thrombosis: a Multicentre Double-Blind Randomized Controlled Trial. "PADIS-TVP" Study.

Resource links provided by NLM:


Further study details as provided by University Hospital, Brest:

Primary Outcome Measures:
  • symptomatic recurrent venous thromboembolism and serious bleedings [ Time Frame: validated standardized objective tests ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • mortality due to another cause than recurrent venous thromboembolism or serious bleeding [ Time Frame: medical report and death certificates ] [ Designated as safety issue: No ]

Estimated Enrollment: 374
Study Start Date: July 2007
Estimated Study Completion Date: November 2017
Estimated Primary Completion Date: November 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 1
18 months of active warfarin therapy
Drug: warfarin
18 months of warfarin therapy
Placebo Comparator: 2
18 months of placebo of warfarin
Drug: placebo of warfarin
18 months of placebo of warfarin therapy

  Show Detailed Description

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients with a first episode of idiopathic proximal deep vein thrombosis who have been treated during 6 months (Plus or minus 15 days) using Vitamin K antagonist with a INR between 2 and 3.

Exclusion Criteria:

  • Age > 18
  • warfarin hypersensibility
  • unwilling or unable to give writting informed consent
  • distal deep vein thrombosis or pulmonary embolism
  • Proximal deep vein thrombosis which was provoked by a reversible major risk factor
  • major thrombophilia (protein C, S or antithrombin deficiency, antiphospholipids antibodies, homozygous factor V Leiden)
  • previous documented episode of proximale deep vein thrombosis or pulmonary embolism
  • other indication for anticoagulant therapy (e.g.:atrial fibrillation, mechanic valve)
  • patient on antithrombotic agent in whom antithrombotic agent should be started again after stopping anticoagulation
  • pregnancy
  • women without contraception
  • planned major surgery in the next 18 months
  • ongoing cancer or cured cancer in less than 2 years
  • serious bleeding risk (e.g.: gastric ulcer)
  • platelet count less than 100 Giga/l
  • Life expectancy less than 18 months
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00740493

Locations
France
CHRU de Brest
Brest, France, 29609
CHU de Grenoble
Grenoble, France, 38043
Centre Hospitalier Pierre Le Damany
Lannion, France, 22303
Centre Hospitalier de Bretagne Sud
Lorient, France, 56322
Centre Hospitalier Universitaire de Nantes
Nantes, France, 44093
Hôpital Européen Georges Pompidou
Paris, France, 75015
AP HP Hôpital Hôtel Dieu
Paris, France, 75004
CHU de POITIERS
Poitiers, France, 86021
Centre Hospitalier de Cornouaille
Quimper, France, 29000
CHU de Rennes
Rennes, France, 35023
Centre Hospitalier de Saint Brieuc
Saint Brieuc, France, 22023
Hôpital de Rangueil
Toulouse, France, 31000
CHU de Tours
Tours, France, 37000
Centre Hospitalier Intercommunal
Vernon, France, 27200
Sponsors and Collaborators
University Hospital, Brest
Investigators
Principal Investigator: Francis Couturaud, MD, PhD EA3878, IFR148
  More Information

No publications provided

Responsible Party: University Hospital, Brest
ClinicalTrials.gov Identifier: NCT00740493     History of Changes
Other Study ID Numbers: RB06.019 PADIS TVP
Study First Received: August 22, 2008
Last Updated: July 7, 2014
Health Authority: France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
France: French Data Protection Authority
France: Institutional Ethical Committee
France: Ministry of Health

Keywords provided by University Hospital, Brest:
recurrent venous thromboembolism
idiopathic deep vein thrombosis
optimal duration of anticoagulation

Additional relevant MeSH terms:
Thromboembolism
Thrombosis
Venous Thrombosis
Venous Thromboembolism
Embolism and Thrombosis
Vascular Diseases
Cardiovascular Diseases
Warfarin
Anticoagulants
Hematologic Agents
Therapeutic Uses
Pharmacologic Actions

ClinicalTrials.gov processed this record on August 26, 2014